Alessandra Ammazzalorso Selected Research

prolinamide

1/2019	The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.
5/2018	Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandra Ammazzalorso Research Topics

Disease

5	Neoplasms (Cancer) 07/2020 - 01/2017
4	Breast Neoplasms (Breast Cancer) 12/2021 - 01/2016
4	Glioma (Gliomas) 07/2020 - 06/2017
4	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2019 - 01/2016
2	Mycoses (Diseases, Fungus) 12/2021 - 01/2019
2	Paraganglioma (Paragangliomas) 05/2020 - 01/2019
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2019 - 04/2019
1	Carcinogenesis 05/2022
1	Triple Negative Breast Neoplasms 05/2022
1	Infections 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Inflammation (Inflammations) 07/2020
1	Parkinson Disease (Parkinson's Disease) 10/2019
1	Hypertension (High Blood Pressure) 07/2019
1	Obesity 07/2019
1	Communicable Diseases (Infectious Diseases) 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 01/2019
1	Cholestasis 10/2018
1	Gallstones (Gallstone) 10/2018
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2017
1	Glioblastoma (Glioblastoma Multiforme) 06/2017
1	Pathologic Processes 10/2016
1	Metabolic Diseases (Metabolic Disease) 05/2016
1	Intellectual Disability (Idiocy) 01/2016
1	Cognitive Dysfunction 01/2016
1	Alzheimer Disease (Alzheimer's Disease) 01/2016
1	Dyslipidemias (Dyslipidemia) 09/2015
1	Insulin Resistance 09/2015

Drug/Important Bio-Agent (IBA)

7	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 05/2016
4	Aromatase InhibitorsIBA 12/2021 - 01/2016
4	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 12/2021 - 05/2018
2	LigandsIBA 01/2022 - 09/2015
2	Aromatase (CYP19)IBA 12/2021 - 11/2021
2	Biological ProductsIBA 12/2021 - 05/2018
2	Fibric Acids (Fibrates)IBA 04/2019 - 09/2015
2	prolinamideIBA 01/2019 - 05/2018
2	Hormones (Hormone)IBA 06/2017 - 01/2016
1	Histone Deacetylases (Histone Deacetylase)IBA 05/2022
1	Histone Deacetylase InhibitorsIBA 05/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2022
1	Amino Acids FDA Link 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	NucleotidesIBA 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	IndazolesIBA 12/2021
1	TriazolesIBA 12/2021
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2020
1	compound 17IBA 07/2020
1	GW 6471IBA 05/2020
1	AntioxidantsIBA 10/2019
1	Monoamine Oxidase (MAO)IBA 10/2019
1	CM544IBA 01/2019
1	acetamidineIBA 01/2019
1	AmidesIBA 01/2019
1	SolutionsIBA 01/2019
1	Antifungal AgentsIBA 01/2019
1	benzothiazoleIBA 01/2019
1	LipidsIBA 10/2018
1	SteroidsIBA 06/2017
1	StilbenesIBA 01/2017
1	ZincIBA 10/2016
1	Matrix Metalloproteinases (MMPs)IBA 10/2016
1	EnzymesIBA 10/2016
1	Nitric Oxide Synthase (NO Synthase)IBA 02/2016
1	Pharmaceutical PreparationsIBA 01/2016
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 01/2016
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2016
1	Protein Isoforms (Isoforms)IBA 01/2016
1	Therapeutic UsesIBA 09/2015
1	Triglycerides (Triacylglycerol)IBA 09/2015

Therapy/Procedure

6	Therapeutics 05/2022 - 05/2018
2	Drug Therapy (Chemotherapy) 05/2022 - 01/2019
1	Radiotherapy 06/2017